Actively Recruiting
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
Led by Nanjing Medical University · Updated on 2024-12-13
300
Participants Needed
5
Research Sites
208 weeks
Total Duration
On this page
Sponsors
N
Nanjing Medical University
Lead Sponsor
B
Beijing Anzhen Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Acute Aortic Syndrome (AAS)/Aortic Aneurysm is a common feature of aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, the authors hypothesized that people with acute aortic syndrome but without hyperlipidemia might benefit from statin treatment.
CONDITIONS
Official Title
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with aortic dissection, ulceration, intramural hematoma, or aortic aneurysm who have undergone aortic arch replacement, endoluminal isolation, or hybrid therapy
- Patients without clinically significant hyperlipidemia but with cardiovascular risk factors such as male aged 45 or older, female aged 55 or older, hypertension, diabetes, chronic kidney disease, obesity, low HDL cholesterol, smoking, alcohol use, or family history of early ischemic cardiovascular disease
- Patients aged between 18 and 85 years, male or female
- Patients who agree to participate and sign informed consent
You will not qualify if you...
- Allergy to statins
- Active liver disease
- Myopathy
- Pregnant or breastfeeding women
- Mental illness or dependence on drugs or alcohol
- Refusal to participate or sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Actively Recruiting
2
The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China, 210029
Actively Recruiting
3
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Actively Recruiting
4
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
5
Beijing Anzhen Hospital
Beijing, China
Actively Recruiting
Research Team
H
Hong Liu, MD
CONTACT
Y
Yong-feng SHAO, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here